Piper Sandler initiated coverage on Vicarious Surgical with a new price target
$RBOT
Industrial Specialties
Health Care
Piper Sandler initiated coverage of Vicarious Surgical with a rating of Overweight and set a new price target of $16.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2022 | $16.00 → $7.00 | Overweight → Neutral | Piper Sandler |
| 1/7/2022 | $16.00 | Outperform | Credit Suisse |
| 12/7/2021 | $15.00 | Outperform | Cowen & Co. |
| 11/5/2021 | $15.00 | Buy | Canaccord Genuity |
| 10/18/2021 | $15.00 | Buy | BTIG |
| 10/7/2021 | $16.00 | Overweight | Piper Sandler |
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
Piper Sandler downgraded Vicarious Surgical from Overweight to Neutral and set a new price target of $7.00 from $16.00 previously
Credit Suisse initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $16.00
Cowen & Co. initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $15.00
10-Q - Vicarious Surgical Inc. (0001812173) (Filer)
8-K - Vicarious Surgical Inc. (0001812173) (Filer)
SCHEDULE 13D/A - Vicarious Surgical Inc. (0001812173) (Subject)
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB:RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the "Company"), today announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System. During the lab, the Vicarious Surgical System operated fully draped for multiple hours while our CMO, Dr. Barry Greene, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted us
WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (OTCQB:RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Results Total operating expenses were $7.5 million in the first quarter of 2026, compared to $15.7 million in the first quarter of 2025, a decrease of 52%. Research and development expenses in the first quarter of 2026 were $5.0 million, compared to $9.4 million in the first quarter of 2025, a decrease of 46%. General and administrative expenses in the
WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB:RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the "Company"), today announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company's targeted design freeze milestone. This milestone represents the first system-level performance evaluation of the Company's three core instruments: needle drivers, fenestrated graspers, and monopolar sc
Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o
Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Sarah Romano as Chief Financial Officer (CFO), effective April 1, 2025. Ms. Romano will oversee Vicarious Surgical's financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the h
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that Randy Clark has been appointed President effective today, January 29, 2024. As Vicarious Surgical prepares for its next phase of growth following the anticipated finalization of the Vicarious Surgical Version 1.0 System ("V1.0"), the newly established role of President is designed to fortify organizational alignment and focus on the Company's long-term needs and objectives. Reporting to Chief Executive Officer Adam Sachs, Mr. Clark will a
Vicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"). Trading on the Company's Common Stock on the NYSE was suspended after market close on March 3, 2026. The NYSE has determined that the Company has fallen below the continued listing standard, requiring listed companies to maintain an average global market capitalization over a con
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will now report financial results for the third quarter ended September 30, 2025 after the market closes on Wednesday, November 12, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 623856. A live and archived webcast of the event will be available at ht
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report financial results for the third quarter ended September 30, 2025 after the market closes on Thursday, November 13, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 623856. A live and archived webcast of the event will be available at https:
SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13D/A - Vicarious Surgical Inc. (0001812173) (Subject)